| 稿件编号： | L3822 |
| 稿件标题： | 产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌临床分布及耐药性分析 |
| 稿件作者： | 毛炎辉; |
| 关键字词： | [关键词] 超广谱β-内酰胺酶；大肠埃希菌；肺炎克雷伯菌；耐药性 |
| 文章摘要： | 目的 调查分析院内产超广谱β-内酰胺酶的大肠埃希菌、肺炎克雷伯菌临床分布及耐药情况。方法 收集我院2007年1月2010年1月临床分离到的大肠埃希菌和肺炎克雷伯菌分别401株和319株，采用纸片扩散法(K-B法)对分离株进行抗菌药物敏感试验和ESBLs筛选和确证试验，并对其临床分布及耐药情况统计分析。结果 720株大肠埃希菌和肺炎克雷伯菌细菌中，产超广谱β-内酰胺酶阳性率为37.9％；其中大肠埃希菌阳性率为42.1％；肺炎克雷伯菌阳性率为32.6％。产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌均对第三代头孢菌素和单环β-酰胺类抗生素呈现高度耐药性，对氨基糖苷类、氟喹诺酮类、磺胺类抗生素也存在较高耐药性，但是对亚胺培南敏感。结论 本院大肠埃希菌和肺炎克雷伯菌ESBLs的检出率高并呈多重耐药性，这些产ESBLs菌分布在不同病区的各种标本中，临床应及时掌握它们的临床分布及耐药特点，合理的应用抗生素、控制ESBLs菌株的传播和流行。 |
| 杂志名称： | 检验医学与临床 |
| 文章刊期： | 2011年08卷04期 |
| 文章栏目： | 论著 |
| 稿件标题（英文）： | Producing extended spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae clinical dist |
| 稿件作者（英文）： | maoyanhui; |
| 关键字词（英文）： | Extended spectrum β-lactamase; Escherichia coli; Klebsiella pneumoniae; Drug resistance |
| 文章摘要（英文）： | Objective Survey of hospital lactamase enzyme β-lactamase of Escherichia coli and Klebsiella pneumoniae clinical distribution and drug resistance. Methods Collected in our hospital from January 2007 to January 2010 clinical isolates of Escherichia coli and Klebsiella pneumoniae 401 and 319, respectively, by disk diffusion method (K-B method) of the isolates and susceptibility to antibiotics ESBLs screening and confirmatory test, and the clinical distribution and resistance of statistical analysis. Result 720 Escherichia coli and Klebsiella pneumoniae bacteria, the yield of extended spectrum β-lactamase-positive rate was 37.9%; which E. coli-positive rate was 42.1%; Klebsiella pneumoniae positive rate was 32.6 %.Producing extended spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae were the third generation cephalosporins, and monocyclic β-lactam antibiotics showed high resistance to aminoglycosides, quinolones, sulfonamides There are also high resistance to antibiotics, but susceptible to imipenem. Conclusion Court of Escherichia coli and Klebsiella pneumoniae the detection rate of ESBLs and showed multiple drug resistance, these strains produce ESBLs in different wards of the various samples, clinical should grasp their clinical distribution and drug resistance characteristics, rational use of antibiotics to control the spread and prevalence of ESBLs strains. |
| 相关信息： |
文件大小：1.19 MB 字数：3059 页数：3 浏览次数：1615 下载次数：148 |
| 免费查看全文 下载PDF阅读器 | |